JUNY SEBASTIAN

Dr. JUNY SEBASTIAN

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2016 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
JKJ. Kurian
J. Kurian
JMJ. Mathew
J. Mathew
KSK. Sowjanya
K. Sowjanya
KCK. R. K. Chaitanya
K. R. K. Chaitanya
MRMadhan Ramesh
Madhan Ramesh
DND. Narayanappa
D. Narayanappa

1 January 2019 in Therapeutic Advances in Vaccines and Immunotherapy
Verified
Journal Article
Open access
PDF file
JSJUNY SEBASTIAN
JUNY SEBASTIAN
PGParthasarathi Gurumurthy
Parthasarathi Gurumurthy
MRMandyam Dhati Ravi
Mandyam Dhati Ravi
MRMadhan Ramesh
Madhan Ramesh
Vaccines used in national immunization programs are considered safe and effective but immunization safety has become as important as the efficacy of vaccination programs. The objective of the study was to detect adverse events following immunization (AEFIs) to all vaccines administered to a pediatric population in India. The prospective active vaccine safety surveillance study enrolled eligible children in the age group 0–5 years receiving vaccination from the immunization center at JSS Hospital, Mysuru. Study participants were monitored at the site for 30 min following vaccination and a telephonic survey was made after 8 days to identify all AEFIs. Causality assessment of the AEFIs were done using a new algorithm developed by the safety and vigilance department of the World Health Organization. The incidence of reported AEFIs was 13.7%. The most frequently reported AEFI was fever (n = 3095, 93.2%) with an incidence of 109.7 per 1000 doses of vaccine administered, followed by persistent crying (n = 69, 2.4 per 1000 doses of vaccine) and diarrhea (n = 57, 2.0 per 1000 doses of vaccine). The majorly implicated vaccine for AEFIs was Pentavac® followed by BCG. Consistent causal association to immunization was observed in 93.4% of cases. A high incidence rate of AEFI was observed in our study population when compared with previous published studies. AEFI surveillance studies help to detect changes in the frequency of adverse events, which may be an alert to consider vaccine quality or identify a specific risk among the local population.

1 January 2021 in Therapeutic Advances in Vaccines and Immunotherapy
Verified
Journal Article
Open access
PDF file
CBChetak Kadabasal Basavaraja
Chetak Kadabasal Basavaraja
JSJUNY SEBASTIAN
JUNY SEBASTIAN
MRMandyam Dhati Ravi
Mandyam Dhati Ravi
SJSheba Baby John
Sheba Baby John
Background: The COVID-19 vaccination program was introduced in India on 16 January 2021. The Government-issued fact sheet was the only source of information regarding Adverse Events Following Immunizations (AEFIs) for these vaccines. The objective of this study was to assess the AEFIs reported following COVID-19 vaccination in a tertiary care teaching hospital. Materials and methods: The spontaneous reporting method was used for data collection for a period of 3 months. A data collection form was designed to collect the data from the study population who reported adverse events. Collected data were analyzed and categorized by severity and seriousness. The causality assessment team performed causality assessment of the AEFIs using the World Health Organization’s causality assessment algorithm. Results: A total of 11,656 doses of COVID-19 vaccine were administered at the study site during the study period, of which 9292 doses were COVISHIELD™ and 2364 doses were COVAXIN™. In all, 445 AEFIs were reported from 269 subjects with an incidence rate of 3.48%. The majority of the subjects with AEFIs belonged to the age group of 18–45 years. Out of the total 445 AEFIs, 418 AEFIs were expected as per the fact sheets, 409 with COVISHIELD™ and 9 with COVAXIN™. Most of the AEFIs [62.02% ( n = 276)] were observed at the system organ class of ‘General disorders and administration site conditions’. After the causality assessment, out of 433 AEFIs to COVISHIELDTM vaccine, 94.22% ( n = 408) of events were categorized to have ‘consistent causal association with immunization’. Out of 12 adverse events following COVAXIN™, 8 (66.66%) events were categorized as ‘consistent causal association with immunization’. All of them recovered from their adverse events without any sequelae. Conclusion: Spontaneous reporting is one of the cheapest methods that can be used for the reporting of AEFI. This method helps health care professionals to identify rare events and potential signals.

7 October 2022 in European Journal of Hospital Pharmacy
Verified
Journal Article
Open access
PDF file
MMMerrin Mathew
Merrin Mathew
SJSheba Baby John
Sheba Baby John
JSJUNY SEBASTIAN
JUNY SEBASTIAN
MRMandyam Dhati Ravi
Mandyam Dhati Ravi
Autoimmune hepatitis (AIH) is a non-contagious, chronic, inflammatory autoimmune disease in which one’s own immune system attacks healthy, normal hepatic cells. The exact cause of AIH is unknown; however, the combination of genetic, environmental (eg, drugs and natural infection) and immunological factors may lead to AIH. AIH may also be potentiated with the use of vaccines: this case reports one such event following immunisation, along with 1 year of follow-up. A female patient in her late 20s presented to the hospital with yellowish discolouration of eyes, urine and stools. Her medical history revealed that she had been vaccinated with the first dose of a COVID-19 vaccine 10 days earlier. She had a history of asymptomatic COVID-19 infection 3 months ago and a history of chronic analgesic consumption for migraine. She was diagnosed as having AIH through extensive clinical and laboratory workup. This case may be an immediate enhancement of a hidden autoimmune disorder triggered by the vaccination. This adverse event following immunisation has an adequate temporal relationship with her COVID-19 vaccine. The causality can be categorised as ‘indeterminate’ and may be considered as a potential signal following COVID-19 vaccination.

1 January 2021 in Therapeutic Advances in Vaccines and Immunotherapy
Verified
Journal Article
Open access
PDF file
RJRony Abraham Jacob
Rony Abraham Jacob
PAPriya Srambical Abraham
Priya Srambical Abraham
FTFeba Rachel Thomas
Feba Rachel Thomas
VNVytila Navya
Vytila Navya
JSJUNY SEBASTIAN
JUNY SEBASTIAN
PGParthasarathi Gurumurthy
Parthasarathi Gurumurthy
India has almost 225 million adolescent girls and they seem to be at a disadvantage, both economically and by their lack of knowledge on human papilloma virus (HPV) vaccine, when compared to adolescent girls of other Asian countries. To assess the prevalence of HPV vaccination and to identify the impact of education in improving the knowledge and perception about the HPV infection and vaccination among the parents of adolescent girls. The prospective interventional study was conducted in four schools within a South Indian City, Mysuru. The informed consent form and the questionnaire were sent home with the identified adolescent girls during the pre-interventional phase. Educational sessions were conducted for the students in their school and an education leaflet was distributed to their parents. Three weeks later, questionnaires were re-administered to the parents via the enrolled girls and their responses were collected. The prevalence of HPV vaccination in the study population was 4.4%. There was a statistically significant improvement in knowledge in the post-interventional phase of the study (p = 0.001), but could not identify a significant change in their perception (p = 0.479). Parents belonging to the socioeconomic class of upper middle and upper lower showed better improvement at the end of the study, with a percentage improvement of 58.93% and 48.44%, respectively. The study proved that the healt care professional can target school children to communicate effectively to their parents on the importance of HPV vaccine as the study clearly observed a positive behavioral change among the study population.

17 August 2020 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
SJSerika Jyrwa
Serika Jyrwa
JSJUNY SEBASTIAN
JUNY SEBASTIAN
VSVeeranna Shastry
Veeranna Shastry